Voyager Therapeutics, Inc.(VYGR)

Description: Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Parkinson's Disease Gene Therapy Genetics Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Huntington's Disease Genzyme Severe Diseases Ataxia Friedreich's Ataxia Monogenic Neuromuscular Disease

---

Home Page: www.voyagertherapeutics.com

VYGR Technical Analysis

75 Sidney Street
Cambridge, MA 02139
United States
Phone: 857 259 5340

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)